Novus Biologicals products are now on bio-techne.com

Recombinant Human TRAILR1/TNFRSF10A Fc Chimera Protein

Images

 
There are currently no images for TRAILR1/TNFRSF10A (347-DR).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Summary
Reactivity HuSpecies Glossary
Applications Bioactivity

Order Details

View Available Formulations
Catalog# & Formulation Size Price

Recombinant Human TRAILR1/TNFRSF10A Fc Chimera Protein Summary

Details of Functionality
Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L‑929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is 1-3 ng/mL in the presence of 6 ng/mL of Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC).
Source
Spodoptera frugiperda, Sf 21 (baculovirus)-derived human TRAIL R1/TNFRSF10A protein
Human TRAIL R1
(Ala109 - Asn239) &
(Thr110 - Asn239)
Accession # AAC51226
IEGRMD Human IgG1
(Pro100 - Lys330)
6-His tag
N-terminus C-terminus
Accession #
N-terminal Sequence
Ala109 & Thr110
Structure / Form
Disulfide-linked homodimer
Protein/Peptide Type
Recombinant Proteins
Gene
TNFRSF10A
Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Note
<0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

Dilutions
  • Bioactivity
Theoretical MW
43 kDa (monomer).
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
46 kDa, reducing conditions
Publications
Read Publications using
347-DR in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Purity
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TRAILR1/TNFRSF10A Fc Chimera Protein

  • APO2
  • CD261 antigen
  • CD261
  • cytotoxic TRAIL receptor
  • Death receptor 4
  • DR4 TRAIL receptor 1
  • DR4
  • TNF-related apoptosis inducing ligand receptor 1
  • TNF-related apoptosis-inducing ligand receptor 1
  • TNFRSF10A
  • TRAIL R1
  • TRAILR1
  • TRAIL-R1
  • TRAILR-1
  • TRAILR1MGC9365
  • tumor necrosis factor receptor superfamily member 10A
  • tumor necrosis factor receptor superfamily, member 10a

Background

Human TRAIL R1 (TNF-related apoptosis inducing ligand receptor 1), also called DR4 (death receptor 4), is a 50 ‑ 57 kDa, 468 amino acid (aa) type 1 transmembrane protein in the TNF R family, designated TNFRSF10A (1 ‑ 3). Of the five receptors for TRAIL (also called APO2 ligand) in humans, TRAIL R1/DR4 and TRAIL R2/DR5 are apoptosis-inducing and share 59% aa identity within the cytoplasmic death domain (aa 365 ‑ 448 of human TRAIL R1) (1 ‑ 3). Rodents do not express TRAIL R1/DR4. Human decoy receptors TRAIL R3 and TRAIL R4 have non-functional death domains but share ~60% aa identity with TRAIL R1 within extracellular TNFR domains (aa 107 ‑ 229), while the secreted TRAIL receptor osteoprotegerin shares only 18% aa identity with TRAIL R1. Trimeric TRAIL engagement of TRAIL R1 induces apoptosis by recruiting a cytosolic death-inducing signaling complex (DISC) that includes the adaptor FADD and caspases 8 and 10 (2 ‑ 6). TRAIL R1 translational modifications, such as O-glycosylation and palmitoylation, promote apoptosis by enhancing oligomerization and presence in lipid rafts, respectively (3 ‑ 6). Recombinant human TRAIL R1 neutralizes the ability of TRAIL to induce apoptosis (1). TRAIL R1 protein is expressed mainly in damaged, infected and malignant cells and can be repressed by hedgehog proteins in oncogenic cells (3, 7, 8). TRAIL R1 is also expressed on hemopoietic cells and influences activities such as monocyte migration (9). On senescent neutrophils, CXCL12/SDF-1 engagement of CXCR4 induces expression of all TRAIL R (7). TRAIL functions in immune surveillance, inducing apoptosis in cancer cells but not normal cells (3, 10, 11). TRAIL R1 surface expression correlates more closely than that of TRAIL R2 with TRAIL induction of apoptosis on tumor cells such as melanoma and chronic lymphocytic and acute myeloid leukemias (6, 12, 13).

  1. Pan, G. et al. (1997) Science 276:111.
  2. Zauli, G. and P. Secchiero (2006) Cytokine Growth Factor Rev. 17:245.
  3. Yang, A. et al. (2010) Curr. Opin. Cell Biol. 22:837.
  4. Rossin, A. et al. (2009) Biohem. J. 419:185.
  5. Psahoulia, F.H. et al. (2007) Mol. Cancer Ther. 6:2591.
  6. Ries, C.R. et al. (2010) Cell Death Dis. 1:e83.
  7. Lum, J.J. et al. (2005) J. Immunol. 175:1232.
  8. Kurita, S. et al. (2010) Oncogene 29:4848.
  9. Wei, W. et al. (2010) Mol. Immunol. 47:2475.
  10. Sung, E-S. et al. (2009) Mol. Cancer Ther. 8:2276.
  11. Mom, C.H. et al. (2009) Clin. Cancer Res. 15:5584.
  12. MacFarlane, M. et al. (2005) Cell Death Differ. 12:773.
  13. Kurbanov, B.M. et al. (2005) J. Invest. Dermatol. 125:1010.

Customers Who Viewed This Item Also Viewed...

375-TL
Species: Hu
Applications: BA
NB100-56618
Species: Hu, Mu
Applications: Flow-CS, Flow, ICC/IF, IHC, IHC-P, WB
NB100-56116
Species: Ma, Hu, Mu, Rt
Applications: Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, Simple Western, WB
943-D3
Species: Hu
Applications: Bind
AF630
Species: Hu
Applications: IHC, Neut, WB
NB120-13550
Species: Hu, Mu, Rt
Applications: ICC/IF, IHC, IHC-P, WB
AF821
Species: Hu, Mu
Applications: WB
NBP2-45312
Species: Hu, Pm, Mu(-)
Applications: Flow, ICC/IF, IHC, IHC-P, WB
NBP2-47480
Species: Hu
Applications: ICC/IF, IHC, IHC-P, WB
NBP3-07168
Species: Pm, Ca, Pm, Hu, Pm, Sq
Applications: Flow, ICC/IF
H00003126-P01
Species: Hu
Applications: ELISA, AP, PA, WB
NB100-56104
Species: Ca, Hu, Mu, Rt
Applications: IHC, IHC-Fr, IHC-P, IP, WB
NBP2-14093
Species: Hu
Applications: IHC, IHC-P, WB
NBP2-61871
Species: Hu
Applications: ELISA, Flow, ICC/IF, IHC, IHC-P, WB
NB100-56118
Species: Ca, Ma, Hu, Mu, Rt
Applications: Flow-IC, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
NB100-56098
Species: Ca, Hu, Mu, Rt
Applications: IHC, IHC-P, IP, WB

Publications for TRAILR1/TNFRSF10A (347-DR)(5)

We have publications tested in 1 confirmed species: Human.

We have publications tested in 3 applications: Bioassay, Neutralization, Western Blot.


Filter By Application
Bioassay
(3)
Neutralization
(1)
Western Blot
(1)
All Applications
Filter By Species
Human
(3)
All Species
Showing Publications 1 - 5 of 5.
Publications using 347-DR Applications Species
Kim E, Kim A Combination effect of equol and TRAIL against human cervical cancer cells. Anticancer Res, 2013-03-01;33(3):903-12. 2013-03-01 [PMID: 23482760] (Bioassay, Human) Bioassay Human
Peppa , Dimitra, Gill , Upkar S, Reynolds , Gary, Easom , Nicholas, Pallett , Laura J, Schurich , Anna, Micco , Lorenzo, Nebbia , Gaia, Singh , Harsimra, Adams , David H, Kennedy , Patrick, Maini , Mala K Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med, 2012-12-17;210(1):99-114. 2012-12-17 [PMID: 23254287] (Neutralization, Human) Neutralization Human
Bellucci R, Nguyen HN, Martin A, Heinrichs S, Schinzel AC, Hahn WC, Ritz J Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J. Clin. Invest., 2012-06-11;122(7):2369-83. 2012-06-11 [PMID: 22684105] (Bioassay, Human) Bioassay Human
Gasparian ME, Chernyak BV, Dolgikh DA, Yagolovich AV, Popova EN, Sycheva AM, Moshkovskii SA, Kirpichnikov MP Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5. Apoptosis, 2009-06-01;14(6):778-87. 2009-06-01 [PMID: 19412666] (Bioassay) Bioassay
He Q, Lee DI, Rong R, Yu M, Luo X, Klein M, El-Deiry WS, Huang Y, Hussain A, Sheikh MS Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene, 2002-04-18;21(17):2623-33. 2002-04-18 [PMID: 11965535] (Western Blot) Western Blot

Reviews for TRAILR1/TNFRSF10A (347-DR) (0)

There are no reviews for TRAILR1/TNFRSF10A (347-DR). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for TRAILR1/TNFRSF10A (347-DR) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional TRAILR1/TNFRSF10A Products

Blogs on TRAILR1/TNFRSF10A

There are no specific blogs for TRAILR1/TNFRSF10A, but you can read our latest blog posts.

Customers Who Bought This Also Bought

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Human TRAILR1/TNFRSF10A Fc Chimera Protein and receive a gift card or discount.

Bioinformatics

Gene Symbol TNFRSF10A
Uniprot